What type of study is this?

This is a Animal Study study (also classified as: In Vitro Study).

What question did this study set out to answer?

This research focuses on developing a FLT3L-based conjugate targeting chemoresistant leukemia stem cells in acute myeloid leukemia.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Laboratory findings show FLT3L-based therapy reduces cell survival in leukemia stem cells, suggesting new treatment options for resistant AML.

This research focuses on developing a FLT3L-based conjugate targeting chemoresistant leukemia stem cells in acute myeloid leukemia.
Developed a ligand-drug conjugate, FL-Fc-DM1, targeting FLT3 in AML cells.
Assessed effects on cell cycle progression, apoptosis, and colony formation in vitro and in vivo.
Compared FL-Fc-DM1's efficacy to DM1 and tested co-treatment with MCL1 and BCL2 inhibitors.
FL-Fc-DM1 induced cell cycle re-entry and apoptosis in chemoresistant leukemia stem cells.
It significantly reduced leukemic burden in animal models and preserved normal hematopoiesis in humanized mice.
Combination therapies with MCL1 and BCL2 inhibitors enhanced cell death in FLT3-ITD-positive AML cells.

Peng et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Laboratory findings show FLT3L-based therapy reduces cell survival in leukemia stem cells, suggesting new treatment options for resistant AML.